CoChat

Hepatic benefits of HCV cure

Calvaruso, Vincenza, Craxì, Antonio · 2020 · Journal of Hepatology
Cited by 110

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

HCV clearance obtained by direct-acting antiviral agents (DAAs) is conceivably linked to an improved outcome at all stages of liver disease. Available data however suggest that the maximum measurable benefit is obtained by treating patients before they reach the stage of compensated advanced chronic liver disease (cACLD). Ideally, all subjects with chronic hepatitis C (CHC) should be treated before development of advanced fibrosis or cirrhosis, since even if sustained virologic response (SVR) reduces in the latter the risk of decompensation and to a lesser degree of hepatocellular carcinoma (HCC) and improves survival, further progression of liver disease and adverse outcomes including hepatic deaths cannot be entirely avoided. The hepatic venous pressure gradient (HVPG) correlates closely to the stage of liver disease. Measurements of HVPG in patients with severe fibrosis or cirrhosis treated with DAAs shows that those with the highest degree of portal hypertension have the lowest probability of a meaningful reduction of portal pressure after SVR, and maintain a significant risk of decompensation. Reduction in liver stiffness is commonly observed in patients with cACLD but its role in predicting prognosis is yet to be demonstrated. Along the same line, in patients with decompensated cirrhosis prevention of further decompensation and of HCC is only weakly associated to SVR. Overall, the main clinical predictors of a high risk of HCC in patients who obtain SVR on DAAs are all indexes strongly reflecting advanced fibrosis and impaired hepatic function. Long term follow up of large real-life cohorts of patients treated at all stages of liver disease, but mainly those with mild to moderate fibrosis, will be needed to confirm the impact of SVR among diverse HCV infected populations and even more to better stratify the patients with higher risk of complications in order to define their correct surveillance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.08.006

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 110

Metadata

Authors
Calvaruso, V., & Craxì, A.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-12
Volume
73
Issue
6
Pages
1548-1556
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3048281202
Cited by
110
References
1
FWCI
7.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatic benefits of HCV cure. https://app.cochat.ai/papers/10.1016/j.jhep.2020.08.006
The paper
Calvaruso, V., & Craxì, A. (2020). Hepatic benefits of HCV cure. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.08.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.